Top-News
Montag,
05.12.2016 13:05
von
PR Newswire
| Aufrufe: 35
Evogen and UCB Announce Collaboration for Further Development of EvoScore™ START for Improved Diagnosis of Epilepsy
Wissenschaftler bei der Arbeit in einem medizinischen Labor (Symbolbild).
© SolStock / E+ / Getty Images
http://www.gettyimages.de
PR Newswire
PHILADELPHIA and ATLANTA, Dec. 5, 2016
PHILADELPHIA and ATLANTA, Dec. 5, 2016 /PRNewswire/ -- Evogen, Inc., a leader in proteomics and genomics-based testing for improved diagnosis and treatment of neurological disorders, and UCB, a global biopharmaceutical company with more than 20 years of experience in the research and development of anti-epileptic drugs, today announced a collaboration for further development of EvoScore™ START, Evogen's new proteomics-based blood test designed to accurately distinguish epileptic seizures from other events.
The accurate diagnosis of epilepsy seizures remains a challenge to physicians and patients. Current diagnostic tools can be cumbersome, expensive and may have sub-optimal accuracy. The considerable time and cost of current diagnostic methods could pose a burden to patients and healthcare systems, and may also result in treatment delays for some epilepsy patients and inappropriate treatment for others.
The EvoScore START test is a new approach to the diagnosis of epileptic seizures. It analyzes the ratio and concentration of key protein biomarkers in a simple blood test format to determine whether an event was actually a seizure, with sensitivity and specificity of 90% or more. It is estimated that only about 15% of suspected seizure-like events are actual epileptic seizures, yet there are no easily available tools that can definitively distinguish a seizure from another event.
"Evogen aims to be the leader in neurology proteomic and genomic testing, and we believe that EvoScore START has the potential to revolutionize the diagnosis of epilepsy," said Todd Wallach, president and chief executive officer of Evogen. "We are accordingly thrilled to work with epilepsy leader UCB to conduct further development of this innovative biomarker-based blood test. We have always admired UCB's long-standing commitment to the epilepsy field and look forward to UCB's expert help in further refining this important new diagnostic tool for epilepsy patients and their healthcare providers."
"UCB is excited about the potential of better diagnostic tests to improve individual experiences for people with epilepsy," explained Jeff Wren, Head of UCB's Neurology Patient Value Unit. "We believe the availability of more accurate and accessible diagnostics, like EvoScore START, may improve time to care for epilepsy patients and could deliver additional value across the broader healthcare system."
Further details of the agreement were not disclosed.
Peter Crino, MD, PhD, is currently chair of the department of neurology at the University of Maryland School of Medicine. His former laboratory at the University of Pennsylvania Perelman School of Medicine conducted key studies of EvoScore START. Dr. Crino added, "Epilepsy is a potentially devastating disease that affects about 65 million patients worldwide, yet diagnosis is too often imprecise and difficult. Our studies show that Evogen's biomarker-based proteomics blood test has the potential to provide clinicians with an accurate and accessible new tool to distinguish true epileptic seizures from the many events that mimic seizures but are in fact attributable to other causes."
Evogen has two poster presentations relevant to EvoScore START at the 2016 AES Annual Meeting:
1 – AES Poster 3.089
Predictive Blood Test for Seizures: Post-hoc Assessment of Plasma Biomarkers
Dec. 5, 2016; 8:00-10:00am
2 – AES Poster 3.156
EEG Has Some Diagnostic Value in a Third of New Patients Who Present to an Epilepsy Center: A Prospective Study
Dec. 5, 2016; 8:00-10:00am
Evogen representatives will be available to discuss EvoScore START and Evogen's neurology genomic tests during the 2016 AES meeting at Booth #341.
About Epilepsy
Epilepsy is a chronic neurological disorder affecting approximately 65 million people worldwide and more than 2 million people in the U.S., where it is the fourth most common neurological disorder. Although epilepsy may be linked to factors such as health conditions, race and age, it can develop in anyone at any age. Approximately one in 26 people will develop epilepsy in their lifetime. There are many different types of epilepsy but the main characteristic of the condition is recurrent seizures. Seizures are classified by the pattern of onset—partial seizures start in one part of the brain and generalized seizures are characterized by widespread involvement of the whole brain.
About UCB in Epilepsy
UCB has a rich heritage in epilepsy with more than 20 years of experience in the research and development of anti-epileptic drugs. As a company with a long-term commitment to epilepsy research, our goal is to address unmet medical needs. Our scientists are proud to contribute to advances in the understanding of epilepsy and its treatment. We partner and create super-networks with world-leading scientists and clinicians in academic institutions, pharmaceutical companies and other organizations who share our goals. At UCB, we are inspired by patients and driven by science in our commitment to support patients with epilepsy.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7,700 people in approximately 40 countries, the company generated revenue of EUR 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.
About Evogen
Evogen, Inc. is a leading developer of diagnostic, detection and sample collection solutions with successful products deployed worldwide. The company is currently focused on achieving leadership in proteomics and genomics-based testing for improved diagnosis and treatment of neurological disorders, offering rapid, accurate and cost effective precision medicine solutions for optimal patient outcomes. Evogen's EvoScore™ START biomarker-based blood test has the potential to help revolutionize the diagnosis of epilepsy. In peer-reviewed clinical studies, EvoScore START demonstrated sensitivity and specificity of 90% or more. It will be available in target markets in 2017. Evogen's EvoScore Genomics comprehensive genomic testing for improved management of epilepsy and other neurological disorders will be launched to neurologists in mid-2017. For more information, visit www.evogen.com.
| Contacts | |
| Evogen Corporate: | Evogen media: |
| Richard St. Clair | Barbara Lindheim |
| | +1 212.584.2276 |
| |
UCB media: |
| | Jim Baxter, (Neurology Communications, UCB) |
| | |
| | +32.2.473.78.85.01 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/evogen-and-ucb-announce-collaboration-for-further-development-of-evoscore-start-for-improved-diagnosis-of-epilepsy-300372646.html
SOURCE Evogen, Inc.
Werbung
Mehr Nachrichten zur UCB S.A. UNSP.ADR 1/2 Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
